Trial: 201807106

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Phase

I/II

Principal Investigator

Kahl, Brad

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov